The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Explore how political divisiveness impacts mental health and amplifies high-functioning depression, and discover strategies ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

A new study from the Texas A&M University School of Public Health provides additional evidence that meditation using ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Hers breaks down the winter blues, what causes them, and research-backed tips for handling this seasonal mood change.